Acute Toxicity of Radiochemotherapy in Rectal Cancer Patients: A Risk Particularly for Carriers of the TGFB1 Pro25 variant
2012 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Acute Toxicity of Radiochemotherapy in Rectal Cancer Patients: A Risk Particularly for Carriers of the TGFB1 Pro25 variant
Schirmer, M. A. ; Mergler, C. P. N.; Rave-Fränk, M. ; Herrmann, M. K. A.; Hennies, S.; Gaedcke, J. & Conradi, L.-C. et al. (2012)
International Journal of Radiation Oncology*Biology*Physics, 83(1) pp. 149-157. DOI: https://doi.org/10.1016/j.ijrobp.2011.05.063
Documents & Media
Details
- Authors
- Schirmer, Markus Anton ; Mergler, Caroline Patricia Nadine; Rave-Fränk, Margret ; Herrmann, Markus Karl Alfred; Hennies, Steffen; Gaedcke, Jochen ; Conradi, Lena-Christin ; Jo, Peter ; Beißbarth, Tim ; Hess, Clemens Friedrich ; Becker, Heinz; Ghadimi, Michael B. ; Brockmöller, Jürgen ; Christiansen, Hans; Wolff, Hendrik Andreas
- Abstract
- Purpose: Transforming growth factor-beta1 is related to adverse events in radiochemotherapy. We investigated TGFB1 genetic variability in relation to quality of life-impairing acute organ toxicity (QAOT) of neoadjuvant radiochemotherapy under clinical trial conditions. Methods and Materials: Two independent patient cohorts (n = 88 and n = 75) diagnosed with International Union Against Cancer stage II/III rectal cancer received neoadjuvant radiation doses of 50.4 Gy combined with 5-fluorouracil-based chemotherapy. Toxicity was monitored according to Common Terminology Criteria for Adverse Events. QAOT was defined as a CTCAE grade >= 2 for at least one case of enteritis, proctitis, cystitis, or dermatitis. Nine germline polymorphisms covering the common genetic diversity in the TGFB1 gene were genotyped. Results: In both cohorts, all patients carrying the TGFB1 Pro25 variant experienced QAOT (positive predictive value of 100%, adjusted p = 0.0006). In a multivariate logistic regression model, gender, age, body mass index, type of chemotherapy, or disease state had no significant impact on QAOT. Conclusion: The TGFB1 Pro25 variant could be a relevant marker for individual treatment stratification and carriers may benefit from adaptive clinical care or specific radiation techniques. (C) 2012 Elsevier Inc.
- Issue Date
- 2012
- Status
- published
- Publisher
- Elsevier Science Inc
- Journal
- International Journal of Radiation Oncology*Biology*Physics
- ISSN
- 0360-3016
- Sponsor
- German Research Foundation (DFG) [KFO 179]